Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 423

1.

The impact of cost sharing of prescription drug expenditures on health care utilization by the elderly: own- and cross-price elasticities.

Li X, Guh D, Lacaille D, Esdaile J, Anis AH.

Health Policy. 2007 Aug;82(3):340-7. Epub 2006 Nov 28.

PMID:
17134787
2.
3.

When patients have to pay a share of drug costs: effects on frequency of physician visits, hospital admissions and filling of prescriptions.

Anis AH, Guh DP, Lacaille D, Marra CA, Rashidi AA, Li X, Esdaile JM.

CMAJ. 2005 Nov 22;173(11):1335-40.

4.
6.

Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, Walker AM, Glynn RJ.

Clin Pharmacol Ther. 2003 Oct;74(4):388-400.

PMID:
14534526
7.

Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia.

Morgan SG, Agnew JD, Barer ML.

Health Policy. 2004 Jun;68(3):299-307.

PMID:
15113641
8.

Comparison of provincial prescription drug plans and the impact on patients' annual drug expenditures.

Demers V, Melo M, Jackevicius C, Cox J, Kalavrouziotis D, Rinfret S, Humphries KH, Johansen H, Tu JV, Pilote L.

CMAJ. 2008 Feb 12;178(4):405-9. doi: 10.1503/cmaj.070587.

9.

Net health plan savings from reference pricing for angiotensin-converting enzyme inhibitors in elderly British Columbia residents.

Schneeweiss S, Dormuth C, Grootendorst P, Soumerai SB, Maclure M.

Med Care. 2004 Jul;42(7):653-60.

PMID:
15213490
10.

Effects of cost sharing on physician utilization under favourable conditions for supplier-induced demand.

Van de Voorde C, Van Doorslaer E, Schokkaert E.

Health Econ. 2001 Jul;10(5):457-71.

PMID:
11466806
11.

Trends and determinants of prescription drug expenditures in the elderly: data from the British Columbia Pharmacare Program.

Anderson GM, Kerluke KJ, Pulcins IR, Hertzman C, Barer ML.

Inquiry. 1993 Summer;30(2):199-207.

PMID:
8314608
12.
13.

Physician gender and changes in drug prescribing after the implementation of reference pricing in British Columbia.

Duetz MS, Schneeweiss S, Maclure M, Abel T, Glynn RJ, Soumerai SB.

Clin Ther. 2003 Jan;25(1):273-84.

PMID:
12637126
14.

The impact of nonreferral outpatient co-payment on medical care utilization and expenditures in Taiwan.

Chen LC, Schafheutle EI, Noyce PR.

Res Social Adm Pharm. 2009 Sep;5(3):211-24. doi: 10.1016/j.sapharm.2008.08.003. Epub 2009 Jan 31.

PMID:
19733822
15.

The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.

Hansen RA, Schommer JC, Cline RR, Hadsall RS, Schondelmeyer SW, Nyman JA.

Res Social Adm Pharm. 2005 Jun;1(2):139-57.

PMID:
17138472
16.
17.

Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Schneeweiss S, Walker AM, Glynn RJ, Maclure M, Dormuth C, Soumerai SB.

N Engl J Med. 2002 Mar 14;346(11):822-9.

18.

The impact of introducing patient co-payments in Germany on the use of IVF and ICSI: a price-elasticity of demand assessment.

Connolly MP, Griesinger G, Ledger W, Postma MJ.

Hum Reprod. 2009 Nov;24(11):2796-800. doi: 10.1093/humrep/dep260. Epub 2009 Jul 22.

PMID:
19625316
19.

Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.

Hartung DM, Carlson MJ, Kraemer DF, Haxby DG, Ketchum KL, Greenlick MR.

Med Care. 2008 Jun;46(6):565-72. doi: 10.1097/MLR.0b013e3181734a77.

PMID:
18520310
20.

Effects of changes in patient cost sharing and drug sample policies on prescription drug costs and utilization in a safety-net-provider setting.

Lurk JT, DeJong DJ, Woods TM, Knell ME, Carroll CA.

Am J Health Syst Pharm. 2004 Feb 1;61(3):267-72.

PMID:
14986557

Supplemental Content

Support Center